[Has interleukin 2 modified the outcome of metastatic kidney cancer?].
Immunotherapy offers a limited but definite hope in the course of metastatic renal cancer. Interferon alpha gives 2% complete remissions and 14% partial responses. Interleukin 2 achieves 5-10% complete remissions and 20% partial responses. The combination of the two agents does not really improve the results. In contrast, culture of TIL cells in the presence of IL-2 provides encouraging results.
Négrier
S
S
Centre Léon-Bérard, Lyon.
Philip
T
T
D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects; D012074:Remission Induction; D014407:Tumor Cells, Cultured
D016898:Interferon-alpha; D007376:Interleukin-2
L'interleukine 2 a-t-elle modifié le devenir du cancer du rein métastatique?